SUMMARY Results are reported from the first prospective study of gout in New Zealand Maoris based on a sample of 388 males and 378 females. At baseline, high mean levels of serum uric acid (SUA) were found, 0-422 ± 0-092 mmol/l (7.05 ± 1 54 mg/100 ml) in males and 0 350 ± 0-091 mmol/l (5.85 1 *52 mg/100 ml) in females. On the basis of traditional criteria (SUA above 0 42 mmol/l (7.0 mg/100 ml) in males and above 0*36 mmol/l (6-0 mg/100 ml) in females) the prevalence of hyperuricaemia was 49 % in males and 42 % in females. The baseline prevalence of gout (8 * 8 % for males and 0 * 8 % for females) and the subsequent 11-year incidence rates (10 * 3 % for males and 4 3 % for females) are discussed in relation to specified SUA classes. When traditional, sex-specific criteria for hyperuricaemia were used, no relationship was found between the prevalence of hyperuricaemia and the incidence of gout. There was, however, a sharp increase in the incidence rate of gout in both sexes when SUA levels were above 0 48 mmol/l (8 0 mg/100 ml). In subjects with a baseline SUA above this level, the age-standardised 11 -year incidence rate of gout was 29 1 % for males and 37.2% for females. A previously unreported relationship linking muscle size to the incidence of gout in males is presented as a major finding of the study. Other risk factors associated with gout were body mass and blood pressure.
New Zealand Maoris have high levels of serum uric acid (SUA) and are at high risk for gout (Lennane et al., 1960; Prior, 1962; Rose et al., 1966) . This paper presents the results of the first prospective epidemiological study of gout and its risk factors in this population, made possible by the recent completion of a longitudinal data base encompassing 3 consecutive epidemiological surveys of a group of New Zealand Maoris: rounds I (1962/63), II (1968/69) , and IIT (1974) . Findings consist of (a) a summary of baseline (round I) data, including the distribution of SUA, age and sex effects on SUA, an-d ine baseline prevalence of gout; and (b) the incidence study (between baseline at round I and the follow-up at round o), in which evidence is presented of a relationship in males between muscle size and the incidence of gout.
Methods
WHO Special Committee recommendations on methodology were followed in most instances. A full description has been previously published (Prior, 1962; . Serum cholesterol was estimated by the method of Abell et al. (1952) and SUA by a non-enzymatic colorimetric technique Accepted for publication January 30, 1978 correlating closely with uricase methods (Buchanan et al., 1965) . Traditional SUA cut-off values above which subjects were considered hyperuricaemic are 0-42 mmol/l (7.0 mg/100 ml) for males and 0.36 mmol/l (6.0 mg/100 ml) for females subjects.* Earlier publications using these data based a diagnosis of gout on the presence of hyperuricaemia (unless the subject was on uricosuric therapy), plus one or more attacks of typical podagra affecting the joints of the great toe or foot. However, in this prospective study of the risk factors for gout it was considered desirable that a diagnosis of gout be independent of the SUA level, thus allowing study of the latter as a risk factor. Furthermore, in a recent study, Snaith and Coomes (1977) Frisancho (1974) .
Results

POPULATION
The age and sex characteristics of the 388 males and 378 females examined at baseline and their follow-up status 11 years later are given in Table 1 . Details of the baseline population samples have been previously published (Prior, 1962; , Female subjects pregnant at baseline were excluded from the incidence study. The population at risk for gout at baseline includes 96 males and 77 females who subsequently died, as well as 20 males and 21 females who were otherwise lost to follow-up; these 2 groups were therefore compared, on the basis of baseline variables with the subjects who were seen at the follow-up survey. Apart from an anticipated age difference, for which some continuous variables were adjusted by means of Z-score transformation, no baseline differences were found between those subjects seen at the follow-up examination and those who died after the baseline survey. Those subjects lost to follow-up were slightly younger than the resurveyed subjects (males: t290 = 2*14, P = 0 *033; females: t299 =2.47, P = 0.014); and in males this group had a lower mean cholesterol (t28 = 3*89, P<0-001). This indicated that mortality and other reasons for dropping out of the study have not adversely affected the assumption that the ' survivor' group was representative of the baseline population at risk for gout. Incomplete data for some subjects have resulted in minor discrepancies between some totals presented in the text and in tables, depending on the variables concerned.
BASELINE DATA
The baseline distribution of SUA values by sex and the mean values by age and sex are shown in Figs. 1 and 2. These distributions are similar to those reported by Hall et al. (1967) for the Framingham population, Mikkelsen et al., (1965) for the Tecumseh Conversion: SI to traditional units -SUA: 1 mg/100 ml s0-0598 mmol/l. study, and Sturge et al. (1977) for a non-random sample of adults in England and Scotland, with the difference that the Maori values are higher overall by about 0*10 mmol/l (2 mg/100 ml).
Regression analyses revealed a positive linear relationship between age and SUA in female subjects. To remove any such age-effect as well as to counteract the skewness of the SUA distributions, Z-score transformations of SUA values were used in the incidence study. On the traditional basis of 0 .42 and 0O36 mmol/l (7.0 and 6 0 mg/100 ml) as the SUA cut-off values for hyperuricaemia, in males and females, respectively, the prevalence of hyperuricaemia at baseline is 49% in males and 42% in females (Table 2) .
Of the 388 males and 378 non-pregnant females examined at baseline, 34 males and 3 females were diagnosed as having gout, a prevalence of 8.8 % and 0*8 %, respectively. Since the small numbers of the latter group preclude statistical analysis, the only cross-sectional differences shown are those between gouty and non-gouty males (Table 3) . (Sunderman, 1975) for hyperuricaemiaj of 0 *48 mmol/l (8.0 mg/100 ml) would be more useful than 0 .42 mmol/l (7.0 mg/ 100 ml).
INCIDENCE OF GOUT
The incidence study was based on 252 males and 279 females who did not suffer from gout at the baseline examination and who were re-examined eleven years later; a response rate of 90% of eligible subjects. Comparisons were made (within each sex) between those subjects who remained free of the disease and those who at the follow up examination reported having had recurrent attacks of gout. Twenty-six males and 12 females reported recurrent podagra affecting the great toe, an incidence of 10 -3 % and 4.3 % in males and females, respectively. The age-standardised attack rate and relative risk of gout within SUA classes is examined in Table 5 .
RISK FACTORS CONTRIBUTING TO GOUT
Those subjects with and those without subsequent gout were compared on the basis of their baseline variables (Table 6 ). Risk factors for gout common to both males and females were found to be weight, BMI, blood pressure, and SUA. Age was a risk factor in females, reflecting the effect of age on SUA; although cross-sectionally the age difference between gouty and non-gouty males (see Table 3 ) was what would be expected in a chronic disease, these groups did not differ significantly for age in the incidence study. In both the cross-sectional and prospective analyses upper arm muscle circumference was greater in gouty males; the difference in females was not significant. Subcutaneous fat and serum cholesterol, greater in gouty than in non-gouty males cross-sectionally, were not risk factors for the incidence of gout. In addition to univariate analyses to determine individual risk factors, step-wise discriminant analysis was undertaken to find the statistically 'best' set of baseline variables which would discriminate between those subjects who developed gout between examinations and those who remained gout-free. In females SUA Z-scores alone provided the best separation and further multivariate analysis was not appropriate. In males, SUA and muscle size, age-adjusted by Z-score transformation, together provided the best discrimination between the two groups (Table 7) .
Discussion
The high prevalence of gout in New Zealand Maoris has now been supported by a study of incidence cases over an 11-year period. The development of a number of new cases in both males and females has allowed some predictive factors to be determined. As would be expected, SUA level was the most important predictor. In subjects with levels above 0.48 mmol/l (8-0 mg/100 ml) the attack rate of gout over the 11-year period was 29.1 % in males and 37.2% in females. This represents a 5-and 10-fold increase respectively, of the risk of subsequent gout relative to the next lower SUA class, 0.36-0.48 mmol/l (6.0-8.0 mg/100 ml). These findings have important implications for the determination of a discrimination value for hyperuricaemia in Maoris, both male and female, and support the suggestion that a single SUA level of 0.48 mmol/l (8.0 mg/100 ml) would be a more useful cut-off level than the traditional sexspecific values. On the Use of this single reference value could provide a more effective basis for intervention programmes. If used with these data, the higher cut-off results in considerably reduced baseline prevalences of hyperuricaemia (26.8% in males and 10.1 % in females) which then parallel very closely the likelihood of developing gout (10 * 3 % in males and 4*3 % in females).
One of the striking findings in this long term study has been the high incidence rate of gout, 37% over the 11-year period, in females with SUA above 0-48 mmol/l (8.0 mg/100 ml). This suggests that the occurrence of clinical gout is dependent to a much greater extent on SUA levels than on sex or other possible precipitating factors. In the majority of populations the number at risk will be extremely small. The Polynesian predisposition to hyperuricaemia, however, sets them apart and places them in the higher risk category.
A relationship between muscle size and the incidence of gout does not appear to be referred to in the literature and is presented as a major finding of this study. The purine-rich nature of muscle tissue suggests one reason why this variable might be implicated, although the correlation between SUA and muscle size (r = 0.237, P = 0.001) disappeared when correlated for BMI (r = 0-010, P = 0.86). Sturge et al. (1977) reported that lean body mass (LBM) was positively correlated with SUA in both sexes, but when entered into step-wise regression together with a measure of total body mass (ponderal index) LBM in males no longer explained a significant amount of SUA variation. A correlation between SUA and LBM (t55 = 6.34 P<0.001) has been reported by Kennedy et al. (1975) ; this result is based on a pooled group of 27 males and 30 females and a sex difference in the effect of LBM on SUA is not reported.
Further evidence that muscularity, in Caucasian males, does not seem to be accompanied by elevated SUA has been reported by Gertler et al. (1951) . In a study of the relationship between SUA and physique, using Sheldon's somatotype approach (Sheldon et al., 1940) a clear correlation was shown with endomorphy (a measure of obesity), but only an equivocal relationship with mesomorphy (a measure of muscularity). Sheldon and his co-workers conclude that 'though it was expected that the muscle mass of the mesomorphs would contribute to their SUA, the dominant mesomorphs did not differ appreciably from the mid-range physiques, thus confirming the lack of correlation between mesomorphy and uric acid'.
The finding of the present study is thus taken as evidence for the existence of a factor in muscle size which is involved in the pathogenesis of gout but which does not seem to be involved by way of elevating SUA. More research is now needed to corroborate and investigate muscle size as a risk factor for gout. The characteristics of gouty versus non-gouty males in both the cross-sectional and the longitudinal analyses certainly highlight their higher blood pressure, greater body mass, greater muscle size, and higher SUA levels. This study now gives some more definite leads towards the prevention of the long-term effects of hyperuricaemia and clinical gout by active intervention in high risk subjects, ie, males and females with SUA levels above 0.48 mmol/l (8.0 mg/100 ml), and particularly males who have both a high SUA level and a large upper arm muscle circumference.
There is still much to be learned concerning uric acid metabolism and gout in Polynesian people. Recent work by Campion et al. (1975) has established that Maoris, both gouty subjects and asymptomatic hyperuricaemics, were capable of binding more sodium urate than Caucasian gouty or hyperuricaemic subjects. This involved binding to albumin but the Maoris also had urate bound to globulins which had not been shown in Caucasians. This indicates a clear abnormality of urate binding and these studies need to be carried further to determine more clearly what part urate binding plays in the differences in SUA levels within and between different Polynesian populations.
A comparison between New Zealand Maoris and Hawaiian Polynesians showed similarities in terms of hypertension, obesity, and diabetes but gout was uncommon in the Hawaiians and uric acid levels were significantly lower than in Maoris (Healey et al., 1966) . This suggests that not all Polynesian groups have the same measure of genetic predisposition to hyperuricaemia. These differences have not as yet been explained.
Progress must now be made with early recognition and intervention in subjects at high risk. Weight reduction and supervised long-term drug therapy will be the cornerstones of this approach.
Further population studies can be justified when undertaken to identify the distribution of SUA and gout with a view to exploring basic mechanisms, particularly those involving body composition and blood pressure. This would include sub-sampling males and females at different SUA levels to measure urate binding and other metabolic pathways.
